NCT00182806CompletedPhase 2
Phase II Study of Irinotecan Followed by Gemcitabine in NSCLC Following Failure of Platinum Based Therapy
Roswell Park Cancer Institute2 sites in 1 country38 target enrollmentStarted: September 1, 2004Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 38
- Locations
- 2
- Primary Endpoint
- Objective response (complete, partial, and stable disease)
Study Overview
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Irinotecan may also increase the effectiveness of gemcitabine. Giving irinotecan together with gemcitabine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan together with gemcitabine works in treating patients with recurrent or progressive stage III or stage IV non-small cell lung cancer.
Detailed Description
OBJECTIVES:
Primary
- Determine the objective response rate (complete and partial response) in patients with recurrent or progressive stage IIIA-IV non-small cell lung cancer treated with irinotecan and gemcitabine.
Secondary
- Determine the median time to progression in patients treated with this regimen.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), meeting 1 of the following stage criteria:
- •Stage IIIA or IIIB disease
- •Progressive disease
- •Stage IV disease
- •Failed 1 prior platinum-based chemotherapy regimen, including adjuvant therapy
- •Measurable or evaluable disease, as defined by 1 of the following criteria:
- •At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR > 10 mm by spiral CT scan
- •Lesions apparent on CT scan that do not meet the criterion for measurability
- •Brain metastases allowed provided patient has received definitive therapy for metastases, is asymptomatic, and has extra-CNS metastases
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Performance status
- •Life expectancy
- •More than 12 weeks
- •Hematopoietic
- •WBC ≥ 3,000/mm^3
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •AST and ALT ≤ 1.5 times normal
- •Alkaline phosphatase < 1.5 times normal
- •Bilirubin ≤ 1.3 mg/dL
- •Creatinine ≤ 1.6 mg/dL OR
- •Creatinine clearance ≥ 50 mL/min
- •Cardiovascular
- •No unstable angina
- •No congestive heart failure
- •No myocardial infarction within the past 3 months
- •No life-threatening ventricular arrhythmia requiring maintenance therapy
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
- •No uncontrolled seizure disorder
- •No uncontrolled diabetes mellitus
- •No active infection requiring systemic therapy
- •No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- •No other unstable or serious condition
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •Not specified
- •Chemotherapy
- •See Disease Characteristics
- •At least 3 weeks since prior chemotherapy
- •Prior irinotecan allowed
- •No prior gemcitabine
- •No more than 1 prior chemotherapy regimen for NSCLC, excluding gefitinib
- •No other concurrent chemotherapy
- •Endocrine therapy
- •Not specified
- •Radiotherapy
- +5 more not shown
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Objective response (complete, partial, and stable disease)
Secondary Outcomes
- Median time to progression
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney CancerKidney CancerNCT00401128The Cleveland Clinic9
Terminated
Phase 2
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder CancerBladder CancerNCT00089128Medical University of South Carolina16
Completed
Phase 2
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic CancerPancreatic CancerNCT00025168Wake Forest University Health Sciences20
Terminated
Phase 2
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney CancerKidney CancerNCT00089102Medical University of South Carolina9
Completed
Phase 1
Irinotecan and Capecitabine in Treating Women With Advanced Breast CancerBreast CancerNCT00083148Roswell Park Cancer Institute12
